Clinical trial · Interventional
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
NCT00622193CI-TRIAL-00026993completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anamorelin HCl | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 1 Active 50 mg
- interventionNames
- Drug: anamorelin HCl
- type
- EXPERIMENTAL
- label
- 2 Active 100 mg
- interventionNames
- Drug: anamorelin HCl
- type
- PLACEBO_COMPARATOR
- label
- 3 Placebo
- interventionNames
- Drug: placebo
Primary outcomes (1)
- measure
- Hand grip strength and body weight
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * stage IIIB or IV NSCLC * eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab Exclusion Criteria: * mixed large and small cell histologies for lung cancer * significant obesity, BMI \> 30
References
Publications (0)
Data not yet available
No reference posted for this study.